Diplomat Pharmacy (DPLO) Reports FDA Approval Under 'Breakthrough Status'
Tweet Send to a Friend
Diplomat Pharmacy (NYSE: DPLO) announced today that it has a contract to distribute Esbriet (pirfenidone), which was approved Oct. 15 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
